BIIB — Biogen Inc.

Summary of Biogen's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Non-GAAP EPS: $1.99; Full Year Non-GAAP EPS: $15.28.
• Total Revenue: $9.9 billion for 2025, up 2% YoY.
• Growth Products Revenue: $3.3 billion for the year, up 19%, with Q4 revenue of over $800 million.
• Free Cash Flow: $2.1 billion for the year; ended with $4.2 billion in cash and marketable securities.
• MS Business: Generated $3 billion in revenue, with resilience noted despite competitive pressures.

2. Strategic Updates and Business Highlights

• Pipeline Expansion: Significant advancements in the pipeline, including priority reviews for iClick and breakthrough designation for Lidofilumab in lupus.
• Product Launches: Successful launches of Lekembi, Skyclaris, Xerxuve, and Calcadi, generating over $1 billion in revenue collectively.
• Market Leadership: Lekembi holds over 60% market share in anti-amyloid therapies.
• Acquisitions: Acquisition of Alcion Therapeutics aimed at improving patient experience with injections.
• Business Development: New collaborations with Vanqua and Dara Therapeutics.

3. Forward Guidance and Outlook

• 2026 Non-GAAP EPS Guidance: Expected to be between $15.25 and $16.25.
• Revenue Outlook: Anticipated mid-single-digit percentage decline in total revenue for 2026, driven by competitive pressures in the MS segment.
• MS Product Revenue: Expected to decline by mid-teen percentages, excluding VUMERITY.
• Investment Focus: Continued investment in prelaunch activities for lupus and nephrology products.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Notable erosion in MS product revenues due to generics and biosimilars, particularly for TECFIDERA and Tysabri.
• Regulatory Risks: Dependence on upcoming Phase III results for new products, with potential delays affecting growth.
• Market Dynamics: The shift to subcutaneous administration for therapies may take time to gain full reimbursement and acceptance.

5. Notable Q&A Insights

• Sales Growth Cadence: Management expects continued sequential growth, with a 70% persistency rate for patients transitioning to maintenance therapy.
• Return to Growth: The timeline for top-line growth return hinges on successful Phase III results and potential acquisitions.
• Commercial Strategy: Focus on reallocating resources from legacy products to growth areas, with an emphasis on building capabilities in new therapeutic areas.
• Pipeline Confidence: High conviction in late-stage programs, particularly Lidofilumab and selzardimab, despite inherent risks in lupus and transplant indications.
• Market Launch Strategy: Selective rollout in Europe for Xerzove due to pricing challenges, with a focus on specific countries rather than a pan-European approach.

This summary encapsulates the key points from Biogen's Q4 2025 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.